Saudi Central Bank grew its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 81.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 29,436 shares of the company’s stock after acquiring an additional 13,170 shares during the period. Saudi Central Bank’s holdings in Zoetis were worth $2,115,000 at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. J. Stern & Co. LLP raised its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares during the period. State Street Corp lifted its position in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after buying an additional 149,382 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after acquiring an additional 189,235 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Zoetis by 5.8% during the 2nd quarter. Deutsche Bank AG now owns 5,851,737 shares of the company’s stock worth $420,506,000 after acquiring an additional 319,709 shares during the period. Institutional investors own 92.80% of the company’s stock.
Analyst Upgrades and Downgrades
ZTS has been the topic of a number of research reports. Piper Sandler lowered their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. Citigroup cut their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Finally, UBS Group dropped their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $107.43.
Zoetis Stock Down 0.1%
Shares of NYSE ZTS opened at $75.70 on Tuesday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The business has a 50-day moving average of $75.58 and a 200-day moving average of $93.26. The firm has a market capitalization of $31.28 billion, a price-to-earnings ratio of 12.47, a PEG ratio of 1.77 and a beta of 0.73. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $155.15.
Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the firm posted $1.76 earnings per share. Zoetis’s quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Recommended Stories
- Five stocks we like better than Zoetis
- 3 Under-the-Radar Defense Stocks With Record Backlogs
- This Korea ETF Has Soared, But the Rally May Not Be Over
- Why Guidewire’s Post-Earnings Plunge May Not Last
- Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
